Mushannen Tasnim, Aleyadeh Rozaleen, Siddiqui Maria, Saqqur Maher, Akhtar Naveed, Mesraoua Boulenouar, Al Jerdi Salman, Melikyan Gayane, Shaheen Yanal, Qadourah Haneen, Chagoury Odette, Mahfoud Ziyad R, Haddad Naim
Department of Neurology, Weill Cornell Medicine-Qatar, Ar-Rayyan, Qatar.
Department of Neurology Hamad Medical Corporation, Weill Cornell Medicine-Qatar, Doha, Qatar.
Front Neurol. 2021 Nov 22;12:758181. doi: 10.3389/fneur.2021.758181. eCollection 2021.
This study aimed to determine the effect of reperfusion therapies on the occurrence of early post-stroke seizures (PSS) in patients with acute ischemic stroke (AIS). Reperfusion therapies are paramount to the treatment of stroke in the acute phase. However, their effect on the incidence of early seizures after an AIS remains unclear. The stroke database at Hamad Medical Corporation was used to identify all patients who received reperfusion therapies for AIS from 2016 to 2019. They were matched with patients of similar diagnosis, gender, age, and stroke severity as measured by National Institutes of Health Stroke Scale (NIHSS) who did not receive such treatment. The rates of early PSS were calculated for each group. The results showed that 508 patients received reperfusion therapies (342 had IV thrombolysis only, 70 had thrombectomies only, and 96 had received both), compared with 501 matched patients receiving standard stroke unit care. Patients who received reperfusion therapies were similar to their matched controls for mean admission NIHSS score (9.87 vs. 9.79; = 0.831), mean age (53.3 vs. 53.2 years; = 0.849), and gender distribution (85 vs. 86% men; = 0.655). The group receiving reperfusion therapies was found to have increased stroke cortical involvement (62 vs. 49.3%, < 0.001) and hemorrhagic transformation rates (33.5 vs. 18.6%, < 0.001) compared with the control group. The rate of early PSS was significantly lower in patients who received reperfusion therapies compared with those who did not (3.1 vs. 5.8%, respectively; = 0.042). When we excluded seizures occurring at stroke onset prior to any potential treatment implementation, the difference in early PSS rates between the two groups was no longer significant (2.6 vs. 3.9%, respectively; = 0.251). There was no significant difference in early PSS rate based on the type of reperfusion therapy either (3.2% with thrombolysis, 2.9% with thrombectomy, and 3.1% for the combined treatment, = 0.309). Treatment of AIS with either thrombectomy, thrombolysis, or both does not increase the risk of early PSS.
本研究旨在确定再灌注治疗对急性缺血性卒中(AIS)患者卒中后早期癫痫发作(PSS)发生情况的影响。再灌注治疗是急性期卒中治疗的关键。然而,其对AIS后早期癫痫发作发生率的影响仍不明确。利用哈马德医疗公司的卒中数据库,识别出2016年至2019年期间所有接受AIS再灌注治疗的患者。将他们与诊断、性别、年龄以及通过美国国立卫生研究院卒中量表(NIHSS)测量的卒中严重程度相似但未接受此类治疗的患者进行匹配。计算每组的早期PSS发生率。结果显示,508例患者接受了再灌注治疗(342例仅接受静脉溶栓,70例仅接受血栓切除术,96例两者均接受),与之相比,501例匹配患者接受标准卒中单元护理。接受再灌注治疗的患者与匹配对照组在平均入院NIHSS评分(9.87对9.79;P = 0.831)、平均年龄(53.3对53.2岁;P = 0.849)以及性别分布(男性分别为85%对86%;P = 0.655)方面相似。与对照组相比,接受再灌注治疗的组卒中皮层受累增加(62%对49.3%,P < 0.001)且出血转化率更高(33.5%对18.6%,P < 0.001)。接受再灌注治疗的患者早期PSS发生率显著低于未接受治疗的患者(分别为3.1%对5.8%;P = 0.042)。当我们排除在任何潜在治疗实施前卒中发作时出现的癫痫发作后,两组早期PSS发生率的差异不再显著(分别为2.6%对3.9%;P = 0.251)。基于再灌注治疗类型的早期PSS发生率也无显著差异(溶栓治疗为3.2%,血栓切除术为2.9%,联合治疗为3.1%,P = 0.309)。采用血栓切除术、溶栓治疗或两者联合治疗AIS不会增加早期PSS的风险。